SLB vs ZBIO · P/E 12, rev $8.97B vs rev $10.0M
Schlumberger NV (SLB) versus Zenas BioPharma, Inc. Common Stock (ZBIO) — a side-by-side from cached financials, not a winner call.
Schlumberger NV (SLB) is a oil & gas equipment & services company listed on US.
Zenas BioPharma, Inc. Common Stock (ZBIO) is a biotechnology company listed on US.
Latest reported SLB revenue for 2026-06-30 was $8.97B. Net income was $786.0M. Revenue was up 2.9% from 2026-03-31 to 2026-06-30. SLB currently screens at market cap $48.16B and trailing P/E 12.1.
Latest reported ZBIO revenue for 2025-12-31 was $10.0M. Net income was -$377.7M. Revenue was up 100.0% from 2024-12-31 to 2025-12-31. ZBIO currently screens at market cap $798.0M.
SLB currently screens at market cap $48.16B and trailing P/E 12.1. ZBIO currently screens at market cap $798.0M.
Not investment advice. Open the SLB and ZBIO stock pages for the full models.
Not investment advice.